905 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by Louisbourg Investments Inc.

Louisbourg Investments Inc. acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 905 shares of the biopharmaceutical company’s stock, valued at approximately $28,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP raised its holdings in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 877 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its holdings in shares of Royalty Pharma by 76.4% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 414 shares during the last quarter. Riverview Trust Co raised its holdings in shares of Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,186 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Royalty Pharma by 160.5% in the fourth quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 1,003 shares during the last quarter. Finally, Westpac Banking Corp acquired a new position in shares of Royalty Pharma in the fourth quarter worth $53,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $35.10 on Tuesday. The company has a market cap of $19.73 billion, a P/E ratio of 24.21, a P/E/G ratio of 2.31 and a beta of 0.48. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $35.38. The business has a fifty day simple moving average of $32.90 and a 200-day simple moving average of $31.04.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities research analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.51%. The ex-dividend date was Friday, May 16th. Royalty Pharma’s dividend payout ratio is currently 47.57%.

Wall Street Analyst Weigh In

RPRX has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on Royalty Pharma in a report on Friday, May 16th. They issued an “overweight” rating and a $51.00 price target for the company. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, March 28th. Finally, Wall Street Zen cut Royalty Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, May 20th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma currently has a consensus rating of “Buy” and an average price target of $47.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.